We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02145130
Previous Study | Return to List | Next Study

Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02145130
Recruitment Status : Completed
First Posted : May 22, 2014
Last Update Posted : September 8, 2021
University Hospital, Zürich
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
The purpose of this study is the evaluation of the safety of autologous tissue-engineered dermal substitutes "denovoDerm" (first arm) and dermo-epidermal skin substitutes "denovoSkin" (second arm) transplanted onto the wound bed in children and adults.

Condition or disease Intervention/treatment Phase
Burn Injury Soft Tissue Injury Skin Necrosis Scars Congenital Giant Nevus Skin Tumors Biological: denovoDerm Biological: denovoSkin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Two Armed, Open, Prospective and Multicentre Study to Evaluate the Safety of Autologous Tissue-engineered Dermal Substitutes and Dermo-epidermal Skin Substitutes for the Treatment of Large Deep Partial and Full Thickness Skin Defects in Children and Adults
Study Start Date : May 2014
Actual Primary Completion Date : March 2021
Actual Study Completion Date : March 2021

Arm Intervention/treatment
Experimental: denovoDerm
Autologous tissue-engineered dermal substitute
Biological: denovoDerm
Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin

Experimental: denovoSkin
Autologous tissue-engineered dermo-epidermal skin substitute
Biological: denovoSkin
Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed

Primary Outcome Measures :
  1. Safety [ Time Frame: denovoDerm: 4-6 days and 21 days after transplantation, denovoSkin 9-11 days and 21 days after transplantation ]
    Assessment/reporting of local infection rate and graft take

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: until 90 days post transplantation ]
    Assessment/reporting of number of adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Deep partial or full thickness skin defect of at least 9 cm2 requiring surgical wound coverage due to:

    1. Acute cases: burn injury, soft tissue injury, skin necrosis after purpura fulminans
    2. Reconstructive cases (elective surgery): scar formation after burn injuries, congenital giant nevus, skin tumours
  • Informed consent by patients/parents or other legal representatives

Exclusion Criteria:

  • Infected wounds or positive general microbiological swabs taken from the nose for multi-resistant germs
  • Patients tested positive for HBV, HCV, syphilis or HIV
  • Patients with known underlying or concomitant medical conditions that may interfere with normal wound healing (e.g. immune deficiency, systemic skin diseases, any kind of congenital defect of metabolism including diabetes)
  • Coagulation disorders as defined by INR outside its normal value, PTT >ULN and fibrinogen <LLN and / or at the Investigator's discretion
  • Previous enrolment of the patient into the current study
  • Participation of the patient in another study within 30 days preceding and during the present study
  • Patients or parents/other legal representatives expected not to comply with the study protocol
  • Suspicion of child abuse
  • Pregnant or breast feeding females
  • Contamination derived from biopsy which could interfere with patients health
  • Due to patient derived variations, isolated cells from biopsy do not proliferate or proliferate insufficiently
  • Skin substitute has not been released due to production specific deviations
  • Patients allergic to amphotericin B and gentamicin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02145130

Layout table for location information
University Children's Hospital Zurich: denovoDerm
Zurich, ZH, Switzerland, 8032
University Children's Hospital Zurich: denovoSkin
Zurich, ZH, Switzerland, 8032
Sponsors and Collaborators
University of Zurich
University Hospital, Zürich
Layout table for investigator information
Principal Investigator: Sophie Böttcher, PD Dr. med. University Children's Hospital, Zurich
Layout table for additonal information
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02145130    
Other Study ID Numbers: EuroSkinGraft / ESG-01-2011
First Posted: May 22, 2014    Key Record Dates
Last Update Posted: September 8, 2021
Last Verified: September 2021
Keywords provided by University of Zurich:
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Soft Tissue Injuries
Pathologic Processes